AR127014A1 - Anticuerpo quimérico biespecífico bivalente que comprende un heterodímero basado en proteínas mhc o proteínas similares a mhc - Google Patents
Anticuerpo quimérico biespecífico bivalente que comprende un heterodímero basado en proteínas mhc o proteínas similares a mhcInfo
- Publication number
- AR127014A1 AR127014A1 ARP220102437A ARP220102437A AR127014A1 AR 127014 A1 AR127014 A1 AR 127014A1 AR P220102437 A ARP220102437 A AR P220102437A AR P220102437 A ARP220102437 A AR P220102437A AR 127014 A1 AR127014 A1 AR 127014A1
- Authority
- AR
- Argentina
- Prior art keywords
- heavy chain
- mhc
- antibody
- bispecific
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere al campo de la biotecnología, específicamente a los anticuerpos quiméricos bivalentes y biespecíficos que incluyen un heterodímero basado en los dominios proximales de membrana del MHC (complejo mayor de histocompatibilidad) o proteínas tipo MHC (CD1 (agrupamiento de diferenciación 1) o HFE (proteína de hemocromatosis)), así como a una técnica para producir dichos anticuerpos biespecíficos. La invención se refiere además a un ácido nucleico que codifica dicho anticuerpo biespecífico, un vector de expresión, una célula huésped para producir dicho anticuerpo quimérico, biespecífico y bivalente, y a un método para producir dicha célula. Reivindicación 1: Un anticuerpo quimérico, bivalente, biespecífico, en donde dicho anticuerpo comprende: a) una primera cadena liviana y una primera cadena pesada del anticuerpo que se une específicamente a un primer antígeno; en donde la primera cadena liviana comprende un dominio variable de cadena liviana y un dominio constante de cadena liviana; en donde la primera cadena pesada comprende un dominio variable de cadena pesada y los dominios constantes de cadena pesada del anticuerpo que incluye un primer (CH1) dominio constante de cadena pesada y un monómero del fragmento Fc que comprende el segundo (CH2) y tercer (CH3) dominios constantes de cadena pesada; b) una segunda cadena liviana y una segunda cadena pesada del anticuerpo de unión específica a un segundo antígeno, en donde la segunda cadena liviana comprende un dominio variable de cadena liviana y un dominio constante que se selecciona del grupo: un primer dominio proximal de membrana del MHC (complejo de histocompatibilidad principal) o un primer dominio proximal de membrana de la proteína tipo MHC; en donde la segunda cadena pesada comprende un dominio variable de cadena pesada, un dominio constante que se selecciona del grupo: un segundo dominio proximal de membrana del MHC (complejo de histocompatibilidad principal) o un segundo dominio proximal de membrana de la proteína tipo MHC; y un monómero del fragmento Fc que comprende el segundo (CH2) y tercer (CH3) dominios constantes de cadena pesada; en donde el primer dominio proximal de membrana del MHC o proteína tipo MHC y el segundo dominio proximal de membrana del MHC o proteína tipo MHC forman un heterodímero entre ellos, que se estabiliza mediante un enlace disulfuro; en donde el dominio CH3 de una cadena pesada y el dominio CH3 de otra cadena pesada se ponen en contacto entre sí con sus superficies, que se modifican para formar un anticuerpo quimérico, bivalente, biespecífico, dichas modificaciones en los dominios CH· de cadena pesada son sustituciones para facilitar la heterodimerización. Reivindicación 67: Un ácido nucleico aislado, que codifica el anticuerpo quimérico, bivalente, biespecífico de acuerdo con cualquiera de las reivindicaciones 1 a 66. Reivindicación 69: Un vector de expresión que comprende el ácido nucleico de acuerdo con cualquiera de las reivindicaciones 67 a 68. Reivindicación 70: Un método para producir una célula huésped para producir un anticuerpo quimérico bivalente, biespecífico de acuerdo con cualquiera de las reivindicaciones 1 a 66, que comprende transformar la célula con el vector de acuerdo con la reivindicación 69. Reivindicación 71: Una célula huésped para producir el anticuerpo quimérico, bivalente, biespecífico de acuerdo con cualquiera de las reivindicaciones 1 a 66, que comprende el ácido nucleico de acuerdo con cualquiera de las reivindicaciones 67 a 68. Reivindicación 72: Un método para producir el anticuerpo quimérico, bivalente, biespecífico de acuerdo con las reivindicaciones 1 a 66, en donde el método comprende las etapas de: a) transformar la célula huésped con vectores de expresión que comprenden moléculas de ácido nucleico que codifican la primera cadena liviana y la primera cadena pesada del anticuerpo quimérico biespecífico, con vectores de expresión que comprenden moléculas de ácido nucleico que codifican la segunda cadena liviana y la segunda cadena pesada del anticuerpo quimérico biespecífico, b) cultivar la célula huésped en condiciones adecuadas para la síntesis de dicho anticuerpo quimérico, bivalente, biespecífico; y c) aislar dicho anticuerpo biespecífico bivalente del cultivo celular.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2021126369A RU2820683C2 (ru) | 2021-09-08 | Двухвалентное биспецифическое химерное антитело, включающее гетеродимер на основе MHC или MHC-подобных белков |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127014A1 true AR127014A1 (es) | 2023-12-06 |
Family
ID=85506866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102437A AR127014A1 (es) | 2021-09-08 | 2022-09-08 | Anticuerpo quimérico biespecífico bivalente que comprende un heterodímero basado en proteínas mhc o proteínas similares a mhc |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20250340613A1 (es) |
| EP (1) | EP4400514A4 (es) |
| JP (1) | JP2024534976A (es) |
| KR (1) | KR20240052854A (es) |
| CN (1) | CN117999285A (es) |
| AR (1) | AR127014A1 (es) |
| AU (1) | AU2022341822A1 (es) |
| CA (1) | CA3231335A1 (es) |
| CL (1) | CL2024000711A1 (es) |
| CO (1) | CO2024002848A2 (es) |
| CR (1) | CR20240125A (es) |
| EC (1) | ECSP24019084A (es) |
| IL (1) | IL311337A (es) |
| MA (1) | MA64893A1 (es) |
| MX (1) | MX2024003039A (es) |
| PE (1) | PE20241207A1 (es) |
| TW (1) | TW202321312A (es) |
| UY (1) | UY39934A (es) |
| WO (1) | WO2023038548A1 (es) |
| ZA (1) | ZA202402161B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240287186A1 (en) * | 2023-02-28 | 2024-08-29 | Regeneron Pharmaceuticals, Inc. | T cell activators and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| NZ618391A (en) * | 2009-07-30 | 2015-07-31 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
| KR20160104636A (ko) * | 2014-01-15 | 2016-09-05 | 에프. 호프만-라 로슈 아게 | 단백질 Ａ-결합이 개선된 Ｆｃ-영역 변이체 |
| EA034921B1 (ru) * | 2014-09-28 | 2020-04-07 | Зе Реджентс Оф Зе Юниверсити Оф Калифорния | Модуляция стимулирующих и нестимулирующих миелоидных клеток |
| CN116396393A (zh) | 2015-10-08 | 2023-07-07 | 酵活英属哥伦比亚省公司 | 包含κ和λ轻链的抗原结合多肽构建体及其用途 |
| EP3512551A4 (en) * | 2016-09-16 | 2020-08-05 | The Brigham and Women's Hospital, Inc. | BLOCUS OF INTERACTIONS OF ALPHAF TOPROTEIN (AFP) WITH MOLECULES ASSOCIATED WITH MICROGLOBULIN BETA2 |
| CA3068270A1 (en) * | 2017-06-21 | 2018-12-27 | Gsbio, Llc | Heterodimeric bispecific antibodies |
| CN116964084A (zh) * | 2021-02-07 | 2023-10-27 | 正大天晴药业集团股份有限公司 | 双特异性抗体 |
-
2022
- 2022-09-07 EP EP22867793.6A patent/EP4400514A4/en active Pending
- 2022-09-07 WO PCT/RU2022/050281 patent/WO2023038548A1/ru not_active Ceased
- 2022-09-07 MX MX2024003039A patent/MX2024003039A/es unknown
- 2022-09-07 CR CR20240125A patent/CR20240125A/es unknown
- 2022-09-07 IL IL311337A patent/IL311337A/en unknown
- 2022-09-07 PE PE2024000401A patent/PE20241207A1/es unknown
- 2022-09-07 AU AU2022341822A patent/AU2022341822A1/en active Pending
- 2022-09-07 US US18/690,298 patent/US20250340613A1/en active Pending
- 2022-09-07 TW TW111133954A patent/TW202321312A/zh unknown
- 2022-09-07 KR KR1020247011490A patent/KR20240052854A/ko active Pending
- 2022-09-07 CN CN202280061075.3A patent/CN117999285A/zh active Pending
- 2022-09-07 MA MA64893A patent/MA64893A1/fr unknown
- 2022-09-07 CA CA3231335A patent/CA3231335A1/en active Pending
- 2022-09-07 JP JP2024515483A patent/JP2024534976A/ja active Pending
- 2022-09-08 AR ARP220102437A patent/AR127014A1/es unknown
- 2022-09-08 UY UY0001039934A patent/UY39934A/es unknown
-
2024
- 2024-03-07 CO CONC2024/0002848A patent/CO2024002848A2/es unknown
- 2024-03-08 CL CL2024000711A patent/CL2024000711A1/es unknown
- 2024-03-08 EC ECSENADI202419084A patent/ECSP24019084A/es unknown
- 2024-03-18 ZA ZA2024/02161A patent/ZA202402161B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4400514A4 (en) | 2025-10-22 |
| CN117999285A (zh) | 2024-05-07 |
| JP2024534976A (ja) | 2024-09-26 |
| CL2024000711A1 (es) | 2024-07-26 |
| MA64893A1 (fr) | 2024-12-31 |
| WO2023038548A1 (ru) | 2023-03-16 |
| CA3231335A1 (en) | 2023-03-16 |
| US20250340613A1 (en) | 2025-11-06 |
| ECSP24019084A (es) | 2024-04-30 |
| AU2022341822A1 (en) | 2024-04-04 |
| TW202321312A (zh) | 2023-06-01 |
| UY39934A (es) | 2023-03-31 |
| CR20240125A (es) | 2024-08-23 |
| EP4400514A1 (en) | 2024-07-17 |
| CO2024002848A2 (es) | 2024-07-18 |
| PE20241207A1 (es) | 2024-06-06 |
| IL311337A (en) | 2024-05-01 |
| KR20240052854A (ko) | 2024-04-23 |
| MX2024003039A (es) | 2024-04-19 |
| ZA202402161B (en) | 2024-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013111533A (ru) | Способы получения мультиспецифичных и мультивалентных антител | |
| JP2025109759A5 (es) | ||
| MX2022001049A (es) | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos. | |
| RU2019131113A (ru) | Способ получения мультиспецифических антител | |
| ES2939555T3 (es) | Método para generar anticuerpos de alta afinidad | |
| EA201691925A1 (ru) | Биспецифические антитела, которые связываются с cd38 и cd3 | |
| RU2018137419A (ru) | Связывающиеся с cd38 и pd-l1 молекулы | |
| AR127014A1 (es) | Anticuerpo quimérico biespecífico bivalente que comprende un heterodímero basado en proteínas mhc o proteínas similares a mhc | |
| AR126556A1 (es) | Anticuerpos de dominios fc heterodiméricos | |
| AR127298A1 (es) | Anticuerpos que se unen a cd30 y cd3 | |
| MX2023014866A (es) | Direccionamiento selectivo de celulas alorreactivas cd70+ huesped para prolongar la persistencia de las celulas t con car alogenicas. | |
| AR116937A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
| AR132066A1 (es) | MOLÉCULA SIMILAR A UN ANTICUERPO QUE COMPRENDE UN HETERODÍMERO DE LA PROTEÍNA HUMANA CD1b (GRUPO DE DIFERENCIACIÓN 1) | |
| AR133487A1 (es) | ANTICUERPOS ANTI-PROTEÍNA A-b, MÉTODOS Y USOS DE ESTOS | |
| CN114539403A (zh) | 靶向人bcma蛋白的兔重组单克隆抗体及应用 | |
| Apiratmateekul et al. | A modified hybridoma technique for production of monoclonal antibodies having desired isotypes | |
| CN117106079A (zh) | 一种抗SDcatcher、GVopti鼠源单克隆抗体、其制备方法及用途 | |
| AR133071A1 (es) | ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4 | |
| JP6952295B2 (ja) | ヒト抗ｈｌａモノクローナル抗体の作製方法 | |
| AR131856A1 (es) | Proteínas de unión a cd40 | |
| AR127806A1 (es) | Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15 | |
| RU2020107311A (ru) | Получение мультиспецифических смесей антител и способы их применения | |
| HK40084777A (en) | Anti-tcr antibody molecules and uses thereof | |
| AR122458A1 (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| PE20240117A1 (es) | Polipeptido especifico para mucina 1 y sus usos |